PURPOSE STATEMENT
A number of breakthrough technologies are being incorporated into novel diagnostics to detect a range of molecular and protein biomarkers including PCR, microarrays, sequencing, proteomics, methylation, and mutation detection. There is a need to bridge basic research and translational research. This meeting will highlight the next generation of diagnostic platforms that encompass the latest trends in microfluidics, point-of-care technologies, in vivo sensing, and consumer-driven products. A panel of experts will focus on translation to the medical community and the key to success in implementation.
TARGET AUDIENCE
Physicians, Pathologist, Oncologist, M.D.s, Ph.D.s, Scientists, Directors, CEOs and Vice Presidents in the areas of molecular pathology, centralized diagnostics, biomedical sciences, molecular diagnostics, oncology and genetics, infectious disease, sequencing, engineering, and business development.
OBJECTIVES
At the conclusion of this activity, participants should be able to:
- Apply novel technologies in daily patient diagnosis
- Implement new diagnostics technologies into the clinic
- Recognize government standards for diagnostic testing
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of California, Irvine School of Medicine and Cambridge Healthtech Institute. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
DESIGNATION STATEMENT
The University of California, Irvine School of Medicine designates this live activity for a maximum of 16 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
GENERAL DISCLOSURE STATEMENT
It is the policy of the University of California, Irvine School of Medicine and the University of California CME Consortium to ensure balance, independence, objectivity and scientific rigor in all CME activities. Full disclosure of conflicts and conflict resolutions will be made prior to the activity in writing via handout materials, insert, or syllabus.
AB 1195 COMPLIANCE STATEMENT
This activity is in compliance with California Assembly Bill 1195, which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. For specific information regarding Bill 1195 and definitions of cultural and linguistic competency, please visit the CME website at www.cme.uci.edu.
ADA STATEMENT
In compliance with the Americans With Disabilities Act, we will make every reasonable effort to accommodate your needs. For any special requests, please call Mari Alvarez at 781 972 5474 on or before April 16, 2012.